AXSM 📈 Axsome Therapeutics - Overview

Axsome Therapeutics, Inc. is a biopharmaceutical company that focuses on developing innovative therapies for central nervous system (CNS) disorders. The company's product portfolio includes Auvelity, a multimodal agent that targets the N-methyl-D-aspartate receptor and is indicated for the treatment of major depressive disorder. Additionally, Axsome Therapeutics has developed Sunosi, a medication designed to treat excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. These commercial products demonstrate the company's commitment to addressing complex CNS disorders.

The company's pipeline is robust, with several investigational medicines in various stages of clinical development. AXS-05, for instance, is in Phase III clinical trials for the treatment of Alzheimer's disease agitation and has also completed Phase II trials for smoking cessation. Another notable candidate is AXS-07, which has completed Phase III trials for the acute treatment of migraine. Furthermore, AXS-12 is in Phase III trials for the treatment of narcolepsy, while AXS-14 has completed Phase III trials for the treatment of fibromyalgia and other conditions. The company is also exploring the potential of solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, in Phase 2 trials for attention-deficit/hyperactivity disorder, major depressive disorder, binge eating disorder, and shift work disorder.

Axsome Therapeutics, Inc. has established a research collaboration agreement with Duke University to evaluate AXS-05 in smoking cessation. This partnership highlights the company's commitment to advancing its pipeline through strategic collaborations. With a strong foundation in CNS disorder research and development, Axsome Therapeutics is well-positioned to address the complex needs of patients with these conditions. The company was incorporated in 2012 and is headquartered in New York, New York, with more information available on its website.

From a financial perspective, Axsome Therapeutics, Inc. is a publicly traded company listed on the NASDAQ stock exchange under the ticker symbol AXSM. Its common stock is classified under the GICS Sub Industry: Pharmaceuticals, and the company's ISIN is US05464T1043. As a biopharmaceutical company, Axsome Therapeutics is subject to the regulatory requirements and industry trends that shape the pharmaceutical sector. With its focus on CNS disorders and robust pipeline, the company is an important player in the development of novel therapies for these complex conditions.